Premium
BRONCHOSPASMOLYTIC EFFECTS OF RU 42173
Author(s) -
FICHELLE J.,
NALINE E.,
FRESLON J.L.,
JOUQUEY S.,
PLASSARD G.,
THOMPSON M.A.,
MILLER P.,
ADVENIER C.
Publication year - 1988
Publication title -
fundamental and clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.655
H-Index - 73
eISSN - 1472-8206
pISSN - 0767-3981
DOI - 10.1111/j.1472-8206.1988.tb00653.x
Subject(s) - bronchoconstriction , histamine , methacholine , acetylcholine , bronchospasm , bronchodilator , salbutamol , isoprenaline , bronchus , guinea pig , chemistry , pharmacology , in vivo , bronchodilator agents , medicine , endocrinology , asthma , biology , respiratory disease , lung , stimulation , microbiology and biotechnology
Summary— The bronchodilator properties of RU 42173, a new beta‐adrenergic stimulant with an original structure, as a cyclic analogue of an arylethanolamine, have been evaluated on different in vitro and in vivo models and compared with those of salbutamol and isoprenaline. RU 42173 equipotently inhibited histamine‐, acetylcholine‐, and KC1‐induced contractions in isolated guinea pig trachea or small bronchus and in isolated human bronchus. When administered to guinea pigs by the IV or aerosol route, RU 42173 dose‐dependently inhibited bronchospasm induced by histamine, acetylcholine, and methacholine. It also inhibited PAF‐induced bronchoconstriction and PAF‐induced hyperreactivity to histamine. Moreover, RU 42173 had a rapid onset and prolonged duration of action. The potency of RU 42173 was similar to that of salbutamol.